Title : Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Pub. Date : 2021 Aug

PMID : 34329577






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma. Etoposide carboxylesterase 2 Homo sapiens